Active Ingredient History
Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and approved for marketing by the FDA and the EMA in 2004; it is sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier than regular human insulin (RHI). When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal. Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alzheimer Disease (Phase 2)
Atrophy (Phase 4)
Cardiovascular Diseases (Phase 3)
Cognitive Dysfunction (Phase 2)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Ketoacidosis (Phase 4)
Diabetic Nephropathies (Phase 4)
Down Syndrome (Phase 1)
Glucagon-Like Peptide 1 (Phase 4)
Glycemic Control (Phase 3)
Healthy Volunteers (Phase 1)
Hyperglycemia (Phase 4)
Liver Cirrhosis (Phase 4)
Myocardial Infarction (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue